MIN-117 (known formerly as WF-516) is an investigational antidepressant which is under development by Minerva Neurosciences for the clinical treatment of major depressive disorder (MDD). It is described as a 5-HT<sub>1A</sub> and 5-HT<sub>2A</sub> receptor antagonist and inhibitor of serotonin and dopamine reuptake, and is also reported to possess affinity for the ñ<sub>1A</sub>- and ñ<sub>1B</sub>-adrenergic receptors. As of May 2015, MIN-117 is in phase II clinical trials for MDD. In December 2019, Minerva announced that MIN-117 was no longer in clinical development for MDD after disappointing results in a phase IIb trial.